Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib + Docetaxel in AIPC
NCT00589420Phase 2Completed
- Sponsor
- Abramson Cancer Center
- Start
- Jul 2007
- Primary completion
- Feb 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sorafenib in prostate cancer (PCa), sponsored by Abramson Cancer Center. Primary endpoint: Prostate Specific Antigen Response Rate at 12 months. Started Jul 2007; status: completed.
02
Drugs
sorafenib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00589420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00589420.